New Posts New Posts RSS Feed - Trilaciclib-Chemo Combo Extends Lives
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Trilaciclib-Chemo Combo Extends Lives

 Post Reply Post Reply
Author
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13192
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Topic: Trilaciclib-Chemo Combo Extends Lives
    Posted: Jul 22 2019 at 10:13pm
Trilaciclib-Chemo Combo Extends Lives of Triple-negative Breast Cancer Patients, Preliminary Phase 2 Findings Show

Trilaciclib, a treatment that protects the bone marrow from the damaging effects of chemotherapy, significantly extends the lives of women with metastatic triple-negative breast cancer receiving a chemotherapy regimen of gemcitabine and carboplatin, G1 Therapeutics announced. Chemotherapy kills tumor cells that divide rapidly. However, a major side effect is that it also kills rapidly-dividing healthy cells, including important stem cells in the bone marrow. Those stem cells produce white blood cells, red blood cells, and platelets. Therefore, most chemotherapy agents cause bone marrow toxicity as a secondary effect. That leads patients to reduce their chemotherapy dose, or stop the treatment, which increases the chances of cancer progression. Trilaciclib, developed by G1 Therapeutics, is a myelopreservation agent meaning it protects the bone marrow from damage caused by chemotherapy. Combining chemotherapy and myelopreservation agents increases the amount of chemotherapy that individuals can tolerate, thus improving patient outcomes. The treatment's protective effects were demonstrated in lung cancer patients, but their need for supportive care and dose reductions is significantly lower. Now, trilaciclib is being evaluated in metastatic triple-negative breast cancer patients a population whose chemotherapy treatment is often limited by bone marrow toxicity. An ongoing, randomized, Phase 2 clinical trial




DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.